Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Algenpantucel-L in resected pancreatic cancer
NCT00255827Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Nov 2005
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of algenpantucel-L in pancreatic cancer (PC), sponsored by Lumos Pharma, Inc. Primary endpoints: Side effects at 6 months, Dose-Limiting Toxicity at 6 months and 1 more. Started Nov 2005; status: completed.
02
Drugs
algenpantucel-L
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00255827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255827.